ライフサイエンスコーパス: Intralipid

1 Intralipid and glucosamine infusions decreased insulin-s

2 Intralipid enhanced pyruvate dehydrogenase (PDH) phospho

3 Intralipid infusion did not alter the time profiles of p

4 Intralipid/heparin or saline infusion was initiated 2 h

5 Accordingly, 30% glucose and 10% Intralipid were infused for 6 h in ten normal lean indiv

6 d occasions combined with 0.9% saline or 10% Intralipid at 100 mL/h.

7 Importantly, 0.5-2% Intralipid, which delivered more FA to the liver than 6

8 st, 6-h infusions of either 6 mM OA or 4-20% Intralipid increased apoB secretion.

9 etion increased only after infusion of 4-20% Intralipid; TG secretion was unchanged by 6 mM OA.

10 mM oleic acid (OA) bound to albumin, 0.5-20% Intralipid, or saline for 3 or 6 h into male C57BL/6J mi

11 6 mM OA and 20% Intralipid each increased secretion of apoB from primary

12 levels increased similarly after either 20% Intralipid or 6 mM OA, TG secretion increased only after

13 Here, we infused 20% Intralipid (a synthetic lipid emulsion) or saline intrad

14 1 mmol/l in both groups) by infusion of 20% Intralipid (60 ml/h) and heparin (900 U/h).

15 els were unaffected by either 6 mM OA or 20% Intralipid, but microsomal triglyceride transfer protein

16 ons with 6 mM OA versus either saline or 20% Intralipid.

17 mic clamps with (n = 26) or without (n = 23) Intralipid and heparin infusion.

18 min(-1)), l-NAME, AICAR + l-NAME, or AICAR + Intralipid (20%, 0.02 ml. kg(-1). min(-1)).

19 ported that a 72-h coinfusion of glucose and Intralipid (GLU+IL) induces insulin resistance and a mar

20 in LPL release after intravenous heparin and Intralipid strongly suggest that GPIHBP1 represents an i

21 Triglyceride micro-emulsions such as Intralipid(R) have been used to reverse cardiac toxicity

22 eral nutrition containing soybean oil-based (Intralipid) or olive oil-based (ClinOleic) lipid emulsio

23 ing free fatty acid levels in fed animals by Intralipid plus heparin infusion caused significant incr

24 rons as well as the synthetic lipid emulsion Intralipid.

25 Also, when infused with glucosamine, Intralipid decreased insulin action below that with gluc

26 Compared with the control group, Intralipid and lactate infusions decreased glucose infus

27 FFAs were increased in seven women by an 8-h Intralipid/heparin (IL/hep) infusion, and the results we

28 subjects to approximately 1 mmol/l by an 8-h Intralipid/heparin (IL/Hep) infusion, whereas they fell

29 sulin clamp period before glucose ingestion, Intralipid/heparin infusion reduced R(d) (4.4 +/- 0.3 vs

30 se 9.3 +/- 0.7 mmol/l) during an intravenous Intralipid/heparin infusion and 7-10 days later during a

31 stulas during intestinal perfusion of lipid (Intralipid, 170 micromol h(-1), chylous lymph) or a dext

32 and after intraduodenal infusions of lipid (Intralipid; 10 ml, 5 kcal).

33 separate study, short-term (50 and 180 min) Intralipid infusion also failed to increase muscle HBP p

34 and kidney, with and without the addition of Intralipid.

35 sma FFA concentration by coadministration of Intralipid plus heparin to nicotinic acid-treated rats (

36 ocedure with the addition of a coinfusion of Intralipid plus heparin (together with NA) to maintain a

37 evels were increased by incremental doses of Intralipid.

38 -fasted rats received a constant infusion of Intralipid or lactate for 5 h, while a control group rec

39 genously via a low- or high-dose infusion of Intralipid plus heparin or endogenously by an infusion o

40 After 2 h of infusion of Intralipid plus heparin, FFA levels increased from 562+/

41 e study day, FFA was elevated by infusion of Intralipid plus heparin.

42 mental conditions, intraduodenal infusion of Intralipid, compared with saline, did not affect plasma

43 Also, an injection of Intralipid released LPL into the plasma of wild-type mic

44 a high fat test meal or by i.v. injection of Intralipid.

45 roM C-SNAFL-1 containing 2.0% (by volume) of Intralipid as a scatterer, the values of the average lif

46 underwent cyclic infusions of glucose and/or Intralipid prior to islet isolation and analysis by quan

47 usion of saline, Intralipid, glucosamine, or Intralipid and glucosamine (n = 8 or 9 for each) for 330

48 n of either emulsion (210 mg/kg) or placebo (Intralipid diluted 1 : 64).

49 s received an additional infusion of saline, Intralipid, glucosamine, or Intralipid and glucosamine (

50 7 each) for an additional 5 h, while saline, Intralipid, or lactate infusion was continued.

51 using an FDA approved nutrition supplement, Intralipid.

52 We conclude that Intralipid infusion into the duodenum at this rate does

53 Our study shows that Intralipid treatment exhibits no harmful effect on tumor

54 In contrast, the Intralipid-induced insulin resistance was accompanied by

55 he same amount of glycerol as present in the Intralipid infusion.

56 ying scatterer concentrations (1.5-3.0 vol % Intralipid).

57 increased above basal during the clamps with Intralipid infusion (P < 0.01 for both).

58 lation was also significantly decreased with Intralipid and lactate infusions.

59 A level was impaired in skeletal muscle with Intralipid and lactate infusions, resulting in two- to t

60 ecreased in individual skeletal muscles with Intralipid infusion (P < 0.05).

61 extensor digitorum longus (EDL) muscles with Intralipid infusion in both clamps (P < 0.05).

62 uxes could be mimicked by infusing rats with Intralipid or corticosterone and were corrected by lepti

63 decreased 47%, significantly more than with Intralipid or glucosamine alone (P < 0.05).